Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse

This study is testing whether adding linvoseltamab (a bispecific antibody that targets two proteins on myeloma cells) to lenalidomide (a standard maintenance therapy) can help newly diagnosed multiple myeloma patients who are already in remission achieve even deeper remissions or recover their remission after relapse. **You may be eligible if...** - You have been diagnosed with newly diagnosed multiple myeloma - You previously received a triplet or quadruplet treatment containing at least two of: an immunomodulatory drug, a proteasome inhibitor, and/or an anti-CD38 antibody - You are currently on lenalidomide maintenance therapy (started within the last 12 months) - Your current response is a partial response, very good partial response, or complete response — or you have recently had a relapse **You may NOT be eligible if...** - You are on a different maintenance therapy - You have had more than one prior treatment line for active myeloma - Your overall health or organ function is too poor Talk to your doctor to see if this trial is right for you.